We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Partners Seek to Develop Rare Monoclonal Antibodies for Therapeutic Use

By LabMedica International staff writers
Posted on 15 Feb 2016
A recently publicized collaborative research agreement is set to boost the use of a high-throughput single cell antibody platform for the discovery of rare monoclonal antibodies for therapeutic use.

Teva Pharmaceutical Industries Ltd. More...
(Petah Tikva, Israel) and AbCellera (Vancouver, BC, Canada) have agreed to collaborate in a research program that will expand the use of AbCellar's proprietary antibody discovery system.

The AbCellera system is based on isolating single antibody-secreting cells in nanoliter-volume chambers, which allows secreted antibodies to be detected within hours with a variety of bead-based and cell-based assay formats. Combining ultra-high-throughput screening with enhanced sensitivity and flexibility means the microfluidic platform can deliver high-quality monoclonal antibody therapeutic candidates with exceptional speed. Small volume chambers ensure that millions of cells can be screened at the same time based on binding properties and antibody function, focusing downstream analysis on potentially high value antibodies. State-of-the art automation during cell processing and recovery, combined with deep technical expertise guarantees the rapid and effective identification of rare antibodies with the desired therapeutic properties.

Under the terms of the agreement, AbCellera will receive an upfront payment, research payments, and will be eligible to receive undisclosed downstream milestone payments associated with the development and approval of therapeutic antibodies.

“We are pleased to work with AbCellera utilizing this company’s novel biologics technology,” said Dr. Michael Hayden, president of global R&D and CSO at Teva Pharmaceutical Industries Ltd. “This agreement will be complementary to our existing antibody discovery process with the potential to strengthen Teva’s capabilities in novel biologics discovery.”

“These are tough problems that need new technologies to move them forward. Our platform brings important advantages to enable the discovery of rare antibodies with defined specificity and functional activity against difficult membrane protein targets,” said Dr. Carl Hansen, president and CEO of AbCellera. “We look forward to a close collaboration with the team of scientists at Teva, and are excited at the chance to help advance this important program.”

Related Links:

Teva Pharmaceutical Industries Ltd.
AbCellera



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Integrated Biochemical & Immunological System
Biolumi CX8
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.